Skip to content

Artiva Biotherapeutics, Inc. ARTV Change in Other Assets

Change in Other Assets at other companies

Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$5K-99.0%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-$84K+80.2%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$866.6K+174%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$1.05M+1,152%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$662K+138%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$949K-116%

Other financials

Income statement

See full
Revenue-
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-67.9%
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentAssets.

The official record: Artiva Biotherapeutics, Inc.’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s change in other assets?
Artiva Biotherapeutics, Inc. (ARTV) reported change in other assets of $40K in Q4 2025.
How has Artiva Biotherapeutics, Inc.'s change in other assets changed year-over-year?
Artiva Biotherapeutics, Inc.'s change in other assets increased by 229.0% year-over-year, from -$31K to $40K.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.